Ligand Pharmaceuticals stock fell 3.2 percent as insiders sold shares

Published on 10/07/2026 at 06:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ligand Pharmaceuticals stock traded at USD 296.94 on October 6, 2026, after a USD 9.83 decline. Q2 revenue rose 33.8 percent to USD 63.69 million.

LGND, US53220K5048, Illustration mit AI erstellt.

Ligand Pharmaceuticals stock (ISIN US53220K5048) traded at USD 296.94 on Nasdaq on October 6, 2026, down USD 9.83, or 3.20 percent, from the prior close of USD 306.77. The move came as investors weighed a recently disclosed insider transaction and the company's latest earnings profile.

Insider sale meets a sharp decline

According to MarketBeat, Chief Legal Officer Andrew Reardon sold 5,000 Ligand shares at an average price of USD 304.07 on October 2, 2026, under a pre-arranged Rule 10b5-1 plan. The filing also showed that he held 31,854 shares after the transaction.

The October 6 trading level sits USD 29.69 below the 52-week high of USD 326.63 and USD 121.05 above the 52-week low of USD 175.89. Market capitalization stood at USD 6.0 billion on October 6, 2026, while trading volume reached 163,739 shares.

Q2 growth supports guidance

Ligand's Q2 2026 results provide a stronger operating counterpoint to the daily decline. MarketBeat reported adjusted earnings per share of USD 2.37, above the USD 1.97 consensus, while revenue reached USD 63.69 million against a USD 61.30 million estimate.

Revenue increased 33.8 percent from the year-earlier quarter, and adjusted EPS rose from USD 1.60 in the comparable period. The company set fiscal 2026 adjusted EPS guidance at USD 9.00-9.50, giving the market a quantified benchmark for the next results cycle.

Ligand describes itself as a royalty aggregator that partners with biopharmaceutical companies and licenses Captisol and NITRICIL technologies. Its investor-relations page says the portfolio includes economic interests in more than 200 development and commercial-stage assets, a structure that makes royalty receipts and partner product performance central to the earnings outlook.

Analysts see upside to consensus target

MarketBeat reported a Buy consensus from 10 covering analysts and an average 12-month price target of USD 337.89. At USD 296.94, the stock price lies 12.1 percent below that consensus target.

Recent published targets include USD 345 from Barclays, USD 358 from HC Wainwright and USD 388 from Bank of America, according to MarketBeat. The spread between those targets and the consensus average highlights how much valuation depends on the durability of royalty growth rather than on one quarter alone.

LGND stock stays below yearly high

Ligand Pharmaceuticals stock was trading at USD 296.94 on Nasdaq on October 6, 2026. The combination of a 3.20 percent daily decline, Q2 revenue growth of 33.8 percent and fiscal 2026 adjusted EPS guidance of USD 9.00-9.50 leaves execution against royalty expectations as the central valuation measure.